Cancer dormancy: Role of cyclin-dependent kinase inhibitors in induction of cell cycle arrest mediated via membrane IgM

Cancer Research

Volumn 58, Issue 4, 1998, Pages 691-697

  Marches, Radu ^a   Scheuermann, Richard H ^a   Uhr, Jonathan W ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; IMMUNOGLOBULIN M;

ANIMAL CELL; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER CELL; CELL CYCLE; CELL CYCLE G1 PHASE; CROSS LINKING; DNA DAMAGE; EFFECTOR CELL; ENZYME INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANTIBODIES, ANTI-IDIOTYPIC; BURKITT LYMPHOMA; CELL CYCLE; CYCLIN-DEPENDENT KINASES; CYCLINS; G0 PHASE; HUMANS; IMMUNOGLOBULIN M; PHOSPHORYLATION; RECEPTORS, ANTIGEN, B-CELL; RETINOBLASTOMA PROTEIN; TUMOR CELLS, CULTURED;

EID: 0032519525     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Levy, R., and Miller, A. R. Therapy of lymphoma directed at idiotypes. Monogr. J. Natl. Cancer Inst., 10: 61-68, 1990.
2. Hsu, F. J., Kwak, L., Campbell, M., Liles, T., Czerwinski, D., Hart, S., Syrengelas, A., Miller, R., and Levy, R. Clinical trials of idiotype-specific vaccine in B-cell lymphomas. Ann. NY Acad. Sci., 690: 385-387, 1993.
3. Vuist, W. M. J., Levy, R., and Maloney, D. G. Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of Bcl-2 protein. Blood, 83: 899-906, 1994.
4. Racila, E., Scheuermann, R. H., Picker, L. J., Yefenof, E., Tucker, T., Chang, W., Marches, R., Street, N. E., Vitetta, E. S., and Uhr, J. W. Tumor dormancy and cell signaling. II. Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice. J. Exp. Med., 181: 1539-1550, 1995.
5. Yefenof, E., Picker, L. J., Scheuermann, R H., Tucker, T. F., Vitetta, E. S., and Uhr, J. W. Cancer dormancy: isolation and characterization of dormant lymphoma cells. Proc. Natl. Acad. Sci. USA, 90: 1829-1833, 1993.
6. Dyke, R. J., McBride, H., George, A. J. T., Hamblin, T. J., and Stevenson, F. K. Idiotypic vaccination against B-cell lymphoma leads to dormant tumour. Cell. Immunol., 132: 70-83, 1991.
7. 1 lymphoma. Cancer Res., 51 (Suppl.): 5045s-5053s, 1991.
8. 1 phase restriction point. Mol. Cell. Biol., 10: 3003-3012, 1990.
9. 1. Cell Growth Differ., 6: 51-57, 1995.
10. 1 tumor and induction of a dormant state in mice chimeric at the major histo-compatibility complex. J. Immunol., 137: 1376-1382, 1986.
11. Marches, R., Racila, E., Tucker, T. F., Picker, L., Mongini, P., Hsueh, R., Vitetta, E. S., Scheuermann, R. H., and Uhr, J. W. Tumor dormancy and cell signalling. III. Role of hypercrosslinking of IgM and CD40 on the induction of cell cycle arrest and apoptosis in B lymphoma cells. Ther. Immunol., 2: 125-136, 1996.
12. Brown, S. L., Miller, R. A., Horning, S. J., Czerwinski, D., Hart, S. M., McElderry, R., Basham, T., Warnke, R. A., Merigan, T. C., and Levy, R. Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with a interferon. Blood, 73: 651-661, 1989.
13. 1 phase progression: cycling on cue. Cell, 79: 551-555, 1994.
14. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell, 81: 323-330, 1995.
15. Nevins, J. R. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science (Washington DC), 258: 424-429, 1992.
16. 1-S-regulatory genes. Mol. Cell Biol., 15: 4215-4224, 1995.
17. Schulze, A., Zerfass, K., Spitkovsky, D., Middendorp, S. Berges, J., Helin, K., Jansen-Durr, P., and Henglein, B. Cell cycle regulation of the cyclin A gene promoter is mediated by a variant E2F site. Proc. Natl. Acad. Sci. USA, 92: 11264-11268, 1995.
18. Bates, S., Bonetta, L., Macallan, D., Parry, D., Holder, A., Dickson, C., and Peters, G. CDK6 (PLSTIRE) and CDK4 (PSKJ3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1. Oncogene, 9: 71-79, 1994.
19. Hinds, P. W., Mittnacht, S., Dulic, V., Arnold, A., Reed, S. I., and Weinberg, R. A. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell, 70: 993-1006, 1992.
20. Serrano, M., Hannon, G. J., and Beach, D. A new regulatory motif in the cell cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond.), 366: 704-707, 1993.
21. Hannon, G. J., and Beach, D. p15INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature (Lond.), 371: 257-261, 1994.
22. INK4/MTS2 related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev., 8: 2939-2952, 1994.
23. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R. Trent, J. M., Lin, D., Mercer, E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
24. 1 cyclin-dependent kinases. Cell, 75: 805-816, 1993.
25. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature (Lond.), 366: 701-704, 1993.
26. 1 cyclin/cdk protein kinase activity, is related to p21. Cell, 78: 67-74, 1994.
27. Matsuoka, S., Edwards, M. C., Bai, C. Parker, S., Zhang, P., Baldini, A., Harper, J. W., and Elledge, S. J. p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitory family, is a candidate tumor suppressor gene. Genes Dev., 9: 650-662, 1995.
28. 1 arrest and apoptosis. Cancer Res., 54: 1169-1174, 1994.
29. Michieli, P., Chedid, M., Lin, D., Pierce, J. H., Mercer, W. E., and Givol, D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res., 54: 3391-3395, 1994.
30. Jiang, H., Lin, J., Su, Z-Z., Collart, F. R., Huberman, E., and Fisher, P. B. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene, 9: 3397-3406, 1994.
31. Parker, S. B., Eichele, G., Zhang, P., Rawls, A., Sands, A. T., Bradley, A., Olson, E. N., Harper, J. W., and Elledge, S. J. p53-independent expression of p21Cipl in muscle and other terminally differentiating cells. Science (Washington DC), 267: 1024-1027, 1995.
32. Lane, D. P. p53, guardian of the genome. Nature (Lond. ), 358: 15-16, 1992.
33. Meikrantz, W., and Schlegel, R. Apoptosis and the cell cycle. J. Cell. Biochem., 58: 160-174, 1995.
34. 1 checkpoint control. Cell, 82: 675-684, 1995.
35. 2-mediated cellular arrest and death. Cancer Res., 56: 475-479, 1996.
36. 1 cyclin-dependent kinase activity during growth arrest of human breast carcinoma cells by prostaglandin A2. Mol. Cell. Biol., 16: 762-770, 1996.
37. Waf1/cip1 protects against p53-mediated apoptosis of human melanoma cells. Oncogene, 14: 929-935, 1997.
38. Picker, L. J., Treer, J. R., Ferguson-Darnell, B., Collins, P. A., Buck, D., and Terstappen, L. W. M. M. Control of lymphocyte recirculation in man: 1. Differential regulation of the peripheral lymph node homing receptor L-selectin on T cells during the virgin to memory cell transition. J. Immunol., 150: 1105-1121, 1993.
39. Matsushime, H., Quelle, D. E., Shurtleff, S. A., Shibuya, M., Sherr, C. J., and Kato, J. D-type cyclin-dependent kinase activity in mammalian cells. Mol. Cell. Biol., 14: 2066-2076, 1994.
40. Chen, P-L., Scully, P., Shew, J-Y., Wang, J. Y. J., and Lee, W-H. Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell, 58: 1193-1198, 1989.
41. 1 cyclins. Cell, 73: 1059-1065, 1993.
42. 1 kinase activity for cdk6, a novel cyclin D partner. Mol. Cell. Biol., 14: 2077-2086, 1994.
43. 1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell, 79: 487-496, 1994.
44. Kip1, a cyclin-CDK inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev., 8: 9-22, 1994.
45. 1 cyclin-dependent kinases. Genes Dev., 9: 1149-1163, 1995.
46. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78: 59-66, 1994.
47. 1 control in retinoblastoma gene-deficient cells, independent of CDK4 activity. Mol. Cell. Biol., 15: 2600-2611.
48. 1 to S phase transition. Mol. Cell. Biol., 15: 2612-2624, 1995.
49. 1 cyclins. Cell, 71: 323-334, 1992.
50. Ewen, M. E., Sluss, H. K., Sherr, C. J., Matsushime, H., Kato, J., and Livingston, D. M. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell, 73: 487-497, 1993.
51. Kato, J., Matsushime, H., Hiebert, S. W., Ewen, M. E., and Sherr, C. J. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase, CDK4. Genes Dev., 7: 331-342, 1993.
52. Kitagawa, M., Higashi, H., Jung, H-K., Suzuki-Takahashi, I., Ikeda, M., Tamai, K., Kato, J-Y., Segawa, K., Yoshida, E., Nishimura, S., and Taya, Y. The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. EMBO J., 15: 7060-7069, 1996.
53. 1-S transition. EMBO J., 13: 4302-4310, 1994.
54. Saha, P., Eichbaum, Q., Silberman, E. D., Mayer, B. J., and Dutta, A. p21CIP1, and Cdc25A. Competition between an inhibitor and an activator of cyclin-dependent kinases. Mol. Cell. Biol., 17: 4338-4345, 1997.
55. Gu, Y., Rosenblatt, J., and Morgan, D. O. Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J., 11: 3995-4005, 1992.
56. Sebastian, B., Kakizuka, A., and Hunter, T. Cdc25M2 activation of cyclin-dependent kinases by dephosphorylation of threonine-14 and tyrosine-15. Proc. Natl. Acad. Sci. USA, 90: 3521-3524, 1993.
57. Poon, R. Y. C, Jiang, W., Toyoshima, H., and Hunter, T. Cyclin-dependent kinases are inactivated by a combination of p21 and Thr-14/Tyr-15 phosphorylation after UV-induced DNA damage. J. Biol. Chem., 271: 13283-13291, 1996.
58. Aprelikova, O., Xiong, Y., and Liu, E. T. Both p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinase. J. Biol. Chem., 270: 18195-18197, 1995.
59. Cherney, B. W., Bhatia, K. G., Sgadari, C., Gutierrez, M. I., Mostowski, H., Pike, S. E., Gupta, G., Magrath, I. T., and Tosato, G. Role of the p53 tumor suppressor gene in the tumorigenicity of Burkitt's lymphoma cells. Cancer Res., 57: 2508-2515, 1997.
60. Steinman, R. A., Hoffman, B., Iro, A., Guillouf, C., Liebermann, D. A., and El-Houseini, M. E. Induction of p21 (WAF-1/C1P1) during differentiation. Oncogene, 9: 3389-3396, 1994.
61. Zhang, W., Grasso, L., McClain, C. D., Gambel, A. M., Cha, Y., Travali, S., Deisseroth, A. B., and Mercer, W. E. p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/ macrophage differentiation. Cancer Res., 55: 668-674, 1995.
62. Datto, M. B., Li, Y., Panus, J. F., Howe, D. J., Xiong, Y., and Wang, X-F. Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc. Natl. Acad. Sci. USA, 92: 5545-5549, 1995.
63. Li, C-Y., Suardet, L., and Little, J. B. Potential role of WAF1/CIP1/p21 as a mediator of TGF-β cytoinhibitory effect. J. Biol. Chem., 270: 4971-4974, 1995.
64. WAF1/CIP1 mediated by STAT1. Science (Washington DC), 272: 719-722, 1996.
65. Su, W-C. S., Kitagawa, M., Xue, N., Xie, B., Garofalo, S., Cho, J., Deng, C., Horton, W. A., and Fu, X-Y. Activation of Statl by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism. Nature (Lond.), 387: 288-292, 1997.
66. Matsumura, I., Ishikawa, J., Nakajima, K., Oritani, K., Tamiyama, Y., Miyagawa, J-I., Kato, T., Miyazaki, H., Matsuzawa, Y., and Kanakura, Y. Thrombopoietin-induced differentiation of a human megakaryoblastic leukemia cell line, CMK, involves transcriptional activation of p21WAF1/Cip1 by STATS. Mol. Cell. Biol., 17: 2933-2943, 1997.
67. 1 growth arrest of murine B-cell lymphomas. Mol. Biol. Cell, 7: 553-564, 1996.
68. Kip1 by negative signaling via the antigen receptor of B cells and positive signaling via CD40. Eur. J. Immunol., 26: 2425-2432, 1996.
69. Reynisdóttir, I., Polyak, K., Iavarone, A., and Massagué, J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β. Genes Dev., 9: 1831-1845, 1995.
70. Kip1. Oncogene, 13: 2447-2457, 1996.